Comparison of the pCR Rate and DFS Among Breast Cancer Patients with Different Hormone Receptor and HER2 Statuses

Yudi Jin(Dalian Medical University), Shengchun Liu(The Affiliated Yongchuan Hospital of Chongqing Medical University), Yuran Dai(The Affiliated Yongchuan Hospital of Chongqing Medical University), Ailin Lan(The Affiliated Yongchuan Hospital of Chongqing Medical University), Linshan Jiang(The Affiliated Yongchuan Hospital of Chongqing Medical University)
Breast Cancer Targets and Therapy
May 1, 2023
10.2147/bctt.s407896
Cited by 7

Related Papers

Increased NF-κB signalling up-regulates BACE1 expression and its therapeutic potential in Alzheimer's disease
|The International Journal of Neuropsychopharmacology|2011|430
Sulfasalazine‑induced ferroptosis in breast cancer cells is reduced by the inhibitory effect of estrogen receptor on the transferrin receptor
|Oncology Reports|2019|223
Diagnostic Value of Circulating Chromogranin A for Neuroendocrine Tumors: A Systematic Review and Meta-Analysis
|PLoS ONE|2015|101
CXCL1 stimulates migration and invasion in ER‑negative breast cancer cells via activation of the ERK/MMP2/9 signaling axis
|International Journal of Oncology|2019|77
Assessment of the predictive role of pretreatment Ki-67 and Ki-67 changes in breast cancer patients receiving neoadjuvant chemotherapy according to the molecular classification: a retrospective study of 1010 patients
|Breast Cancer Research and Treatment|2018|74